phospholipase A2 group XIIA pseudogene 2Genealiases: []
Q-omics provides the consensus-scored PLA2G12AP2 profile across patient tissues and cancer cell-line models. PLA2G12AP2 expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, PLA2G12AP2 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, PLA2G12AP2 RNA expression shows 6,487 significant gene co-expression associations, with the highest sampling consensus in THCA. Together, these results highlight PAAD, KIRC, and THCA as cancer lineages where PLA2G12AP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLA2G12AP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLA2G12AP2 survival associations across molecular data types. PLA2G12AP2 RNA expression shows survival associations in the most cancer types (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLA2G12AP2 RNA expression–survival associations across cancer types. High PLA2G12AP2 expression shows unfavorable associations in PAAD, LGG, STAD and KIRP, but favorable associations in OV. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for PLA2G12AP2 RNA expression.
This table summarizes PLA2G12AP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PLA2G12AP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLA2G12AP2 shows lower tumor expression in KIRC, KIRP and THCA. The KIRC box plot shows higher PLA2G12AP2 RNA expression in normal versus tumor tissue (log2 FC = −0.080, t-test p = .001).
This table shows molecular features associated with PLA2G12AP2 in patient tissues and cancer cell lines. In patient samples, PLA2G12AP2 shows the broadest associations at the RNA and protein expression levels, with THCA recurring as the lineage with the largest associated feature set.
